Should coronary artery bypass graft surgery patients with mild or moderate aortic stenosis undergo concomitant aortic valve replacement? A decision analysis approach to the surgical dilemma by Smith, William T. et al.
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hould Coronary Artery Bypass Graft Surgery
atients With Mild or Moderate Aortic Stenosis
ndergo Concomitant Aortic Valve Replacement?
Decision Analysis Approach to the Surgical Dilemma
illiam T. Smith IV, MD,* T. Bruce Ferguson, JR, MD,† Thomas Ryan, MD, FACC,*
arolyn K. Landolfo, MD, FACC,* Eric D. Peterson, MD, MPH, FACC*
urham, North Carolina; and New Orleans, Louisiana
OBJECTIVES This study utilizes Markov decision analysis to assess the relative benefits of prophylactic
aortic valve replacement (AVR) at the time of coronary artery bypass graft surgery (CABG).
Multiple sensitivity analyses were also performed to determine the variables that most
profoundly affect outcome.
BACKGROUND The decision to perform CABG or concomitant CABG and AVR (CABG/AVR) in
asymptomatic patients who need CABG surgery but have mild to moderate aortic stenosis
(AS) is not clear-cut.
METHODS We performed Markov decision analysis comparing long-term, quality-adjusted life outcomes
of patients with mild to moderate AS undergoing CABG versus CABG/AVR. Age-specific
morbidity and mortality risks with CABG, CABG/AVR, and AVR after a prior CABG were
based on the Society of Thoracic Surgeons national database (n  1,344,100). Probabilities
of progression to symptomatic AS, valve-related morbidity, and age-adjusted mortality rates
were obtained from available published reports.
RESULTS For average AS progression, the decision to replace the aortic valve at the time of elective CABG
should be based on patient age and severity of AS measured by echocardiography. For patients
under age 70 years, an AVR for mild AS is preferred if the peak valve gradient is25 to 30 mm
Hg. For older patients, the threshold increases by 1 to 2 mm Hg/year, so that an 85-year-old
patient undergoing CABG should have AVR only if the gradient exceeds 50 mm Hg. The AS
progression rate also influences outcomes. With slow progression (3 mm Hg/year), CABG is
favored for all patients with AS gradients 50 mm Hg; with rapid progression (10 mm
Hg/year), CABG/AVR is favored except for patients 80 years old with a valve gradient 25
mm Hg.
CONCLUSIONS This study provides a decision aid for treating patients with mild to moderate AS requiring
CABG surgery. Predictors of AS progression in individual patients need to be better
defined. (J Am Coll Cardiol 2004;44:1241–7) © 2004 by the American College of
Cardiology Foundationa
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Matients diagnosed with coronary disease requiring coronary
rtery bypass graft surgery (CABG) may also have mild to
oderate aortic stenosis (AS) (1). Co-presentation with
oth coronary and valve disease is increasing as the age of
atients referred for CABG surgery rises. If AS is severe
2,3) or the patient has symptoms, aortic valve replacement
AVR) should be performed in conjunction with CABG
urgery (4,5). There is controversy, however, over the
ppropriate care of asymptomatic patients with mild or
oderate stenosis (1,4–7). If no intervention is done at the
ime of CABG, AS symptoms may develop, necessitating a
econd open-heart procedure (AVR), with additional tech-
ical challenges and complications (1,6,8–10). Conversely,
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eorgia.
Manuscript received January 23, 2004; revised manuscript received April 20, 2004,iccepted June 7, 2004.n initial CABG/AVR increases the initial operative risk
nd exposes patients to potential long-term valve-related
omplications (11). Numerous clinical factors, including
everity and rate of progression of AS, patient life expect-
ncy, and probability of valve- or operative-related compli-
ations, must be considered in making this decision.
This study utilizes Markov decision analysis to assess the
elative benefits of prophylactic AVR. Multiple sensitivity
nalyses were also performed to determine the variables that
ost profoundly affect outcome, and to recommend treat-
ent thresholds.
ETHODS
arkov decision analysis. A Markov decision analysis
ynthesizes probabilities of multiple clinical outcomes in the
ssessment of competing treatment strategies (12). The
arkov model structure utilized in this study is represented
n Figure 1. The model evaluates CABG/AVR or CABG
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AVR for Mild to Moderate AS at Time of CABG September 15, 2004:1241–7lone as initial therapy in a patient with mild or moderate
symptomatic AS in whom a CABG is indicated. Patients
ho survive the index surgery without morbidity are initially
n the “alive without events” state. Those who suffer
perative morbidity are placed in the “alive with morbidity”
tate, and those who die as a result of operation are placed
n the absorbing state, “dead.”
There are potential transitions to other health states
uring each Markov cycle (one month in our model) that
epend on the patients’ current state of health. Those who
urvive CABG alone may develop AS symptoms, remain
live without symptoms, or die of other causes. If symptoms
evelop, a reoperation for AVR may be performed or the
atient may not be an operative candidate, in which case he
r she transitions to the “alive with symptomatic AS” state.
imilarly, if AVR is performed (initially or when AS
ymptoms develop), patients may remain alive without
omplication, die of other causes, or develop complications
elated to the valve. In each health state, there are proba-
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
AS  aortic stenosis
AVR  aortic valve replacement
CABG coronary artery bypass graft surgery
CAD  coronary artery disease
QALY  quality-adjusted life year
STS  Society of Thoracic Surgeons
igure 1. Schematic representation of Markov decision model structure.
S aortic stenosis; AVR aortic valve replacement; CABG coronarytrtery bypass graft surgery.ilities of transitioning to another state or dying of a
ompeting morbidity, as shown in Figure 1.
ssumptions. Several assumptions were made to simplify
he decision analysis. The population was assumed to be free
rom non-cardiac life-threatening morbidity. There were
either explicit indications nor contraindications for warfa-
in anticoagulation therapy. We also assumed all patients
ndergoing AVR would receive a mechanical prosthesis. In
ensitivity analysis, the alternative strategy of using a bio-
rosthetic valve in patients over 70 years of age was assessed
13). With this strategy, the model was modified to elimi-
ate valve-related complications, substituting the possibility
f valve deterioration.
nput variables. All input variables and their sources are
oted in Table 1. Age-specific mortality was obtained from
he 1998 U.S. life tables (14). Excess mortality in patients
ith coronary artery disease and AS (15,16) as well as excess
ortality in patients who develop morbidity (17) were
dded to these rates. Operative mortality was obtained from
he Society of Thoracic Surgeons (STS) national database
18). Age- and procedure-specific mortality rates were
rouped by decade as shown in Table 2, and linear inter-
olation was used to extrapolate an age-specific rate for a
atient between the given age ranges. The rate of mortality
mong patients with symptomatic AS was abstracted from
ublished reports (19), as were the likelihoods of complica-
ion or morbidity from a mechanical valve (20).
The risk of developing symptoms was modeled after Otto
t al. (9). A linear least-squares regression was performed to
efine a rate of symptom development for patients at
ariable valve gradients. To interpolate over a continuous
ange of valve gradients, the probability of developing AS
ymptoms without any echo gradient was defined as 0, and
he probability with a gradient of 5.5 m/s was 0.99. The
raction of patients who develop symptomatic AS but are no
onger surgical candidates (or who decline surgery) was also
odeled after the Otto et al. (9) data.
In the sensitivity analysis of bioprosthetic valves, the
robability of spontaneous valve deterioration was modeled
fter Birkmeyer et al. (21) and varies according to patient
ge and the time since valve implant, or 3.48 · exp[9.92
.358 · (patient age  60/10) · (years since implant)2.48].
ortality and morbidity of a repeat AVR for valve deteri-
ration were assumed to be equal to those of an AVR
ollowing CABG.
uality-of-life adjustments. Absolute survival and
uality-adjusted survival were calculated for each manage-
ent strategy. Future years of life were discounted at a rate
f 3% per year (22). The utility of a year of life with
ignificant morbidity, including symptomatic AS (23),
troke (24), permanent renal failure (24), and long-term
orbidity from hemorrhagic complications (25), was dis-
ounted at a rate of 0.50. The relative utility of a year of life
n chronic warfarin anticoagulation therapy was 0.99 rela-
ive to no anticoagulation therapy (26).
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September 15, 2004:1241–7 AVR for Mild to Moderate AS at Time of CABGensitivity analyses. Multiple sensitivity analyses were
erformed to test the stability of our model with variation of
elected model input parameters within reasonable ranges
Table 1). The decision tree shown in Figure 1 was
onstructed, and all the analyses described above carried out
sing DATA (TreeAge Software Inc., Williamstown,
assachusetts).
ESULTS
cute surgical risks. Between 1995 and 2000, 1,344,100
atients underwent CABG, CABG/AVR, or AVR after a
rior CABG in the STS national database. Mortality and
orbidity rates for these procedures stratified by patient age
re shown in Table 2. The operative mortality increased
ith increasing age for each respective operation, from
.33% for a patient under age 55 years undergoing CABG
lone, to 11.34% for a patient over age 75 years undergoing
VR after a prior CABG. Operative mortality was higher
or a patient undergoing AVR after CABG than for a
able 1. Model Input Variables
urgical mortality and morbidity Age-
ge-related mortality Age-
xcess population mortality with CAD and AS (%)
xcess mortality with permanent morbidity (%)
ortality with symptomatic AS (%)
ate of AS progression (mm Hg/yr)
robability of developing AS symptoms Relat
robability of refusing AVR or nonsurgical candidate when
AS symptoms develop (%)
erious bleeding after AVR (%/yr)
ermanent morbidity after bleeding complication (%)
ortality after bleeding complication (%)
hromboembolic risk after AVR (%/yr)
ermanent morbidity after thromboembolism (%)
ortality after thromboembolism (%)
ALY survival with morbidity (yrs)
tility of anticoagulation therapy (yrs)
iscount for future life-years relative to current year of life (%)
S  aortic stenosis; AVR  aortic valve replacement; CAD  coronary artery dis
Table 2. Mortality and Morbidity Rates by Ag
National Database, 1995–2000
<55
CABG only (n) 231,448
Operative mortality (%) 1.33
Permanent stroke (%) 0.54
Renal failure complication (%) 1.59
CABG/AVR (n) 4,036
Operative mortality (%) 4.01
Permanent stroke (%) 0.89
Renal failure complication (%) 3.57
AVR only (with prior CABG) (n) 142
Operative mortality (%) 4.23
Permanent stroke (%) 4.23
Renal failure complication (%) 0.00CABG  coronary artery bypass graft surgery; other abbreviationsatient undergoing simultaneous CABG/AVR, as was the
isk of developing a morbid complication. The risk of
ermanent stroke or renal failure for a patient undergoing
urgery that involved AVR (either at the time of CABG or
ubsequently) was about twice the risk of CABG alone.
ife expectancy from Markov modeling. A hypothetical
5-year-old patient with asymptomatic AS of varying severity
emonstrates the model’s major findings. The quality-adjusted
ife expectancy for such a patient undergoing CABG varies
rom 8.6 years with a baseline valve gradient of 50 mm Hg, to
.1 years for a valve gradient of 10 mm Hg. Alternatively, the
urvival rate after initial CABG/AVR is 8.9 years. Therefore,
ABG alone is superior at lower baseline valve gradients, and
nitial CABG/AVR is the best management if the gradient is
ver 30 mm Hg.
Absolute mathematical event rates for a 65-year-old
atient with a baseline peak aortic gradient of 30 mm Hg
nd an average rate of AS progression (5 mm Hg/year) are
hown in Table 3. Because of perioperative risks from
Value Range Source
rocedure-specific 75%–125% of rate STS database
c — U.S. life tables (14)
1.4/yr 1.1–1.4 (15, 16)
3.75/yr — (17)
23.9/yr 9.6–35.8 (19)
5 1–13 (1,9)
baseline valve gradient 75%–125% of rate (9)
7.7 3.8–15.4 (9)
2.7 1.3–6.2 (20)
22 — (20)
12.2 6–24 (20)
0.7 0.3–1.3 (20)
67.5 — (20)
4.4 2.2–8.8 (20)
0.5 0.4–0.75 (23–25)
0.99 0.9–1.0 (26)
3 annually 1–5 (22)
ALY  quality-adjusted life year; STS  Society of Thoracic Surgeons.
ith Various Operations From the STS
Age Group (yrs)
55–64 65–74 >75
332,938 437,500 260,452
1.85 3.17 5.69
0.99 1.94 3.00
2.35 4.02 6.5
10,030 27,784 34,852
3.87 5.55 8.65
1.73 2.87 4.59
4.79 6.60 9.52
576 1,926 2,416
8.68 8.20 11.34
3.47 3.01 4.55
6.25 6.96 11.26and p
specifi
es toe Was in Table 1.
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AVR for Mild to Moderate AS at Time of CABG September 15, 2004:1241–7ombined CABG/AVR, the immediate post-surgical out-
ome is superior for patients receiving CABG alone. Over
ime, patients who initially receive CABG develop symp-
oms due to AS and require reoperation. Subsequent mor-
idity and mortality eventually exceed the up-front surgical
isk of a combined CABG/AVR.
ffect of varying patient age and baseline aortic valve
radient. Patient age and peak aortic valve gradient by echo
ere important variables in determining treatment when
rogression of AS is constant. Figure 2 displays the thresh-
ld at which CABG alone is superior to CABG/AVR,
arying age and peak valve gradient. Coronary artery bypass
raft surgery alone is preferred in older patients because
educed life expectancy diminishes the likelihood that AS
ill progress to symptoms. A 60-year-old patient with a
radient of 30 mm Hg should have CABG/AVR, but an
0-year-old patient with the same gradient should undergo
ABG alone, according to our data.
Mathematical differences in survival for patients under-
oing CABG alone versus CABG/AVR are shown in Table
across a range of patient ages and baseline aortic valve
radients. Positive values indicate longer survival (in
igure 2. Using quality-adjusted survival as the outcome measure, at low
aseline gradients and in older patients, CABG alone is the preferred
trategy for management of a patient with mild, asymptomatic aortic
tenosis undergoing coronary bypass surgery. CABG/AVR is favored for
atients of all ages with a valve gradient over 50 mm Hg, and for patients
nder age 70 once their valve gradient reaches about 28 mm Hg. This
ssumes a constant rate of AS progression of 5 mm Hg/year. Abbreviations
able 3. Modeled Event Rates Over Time for a 65-Year-Old
atient With Baseline Peak Aortic Valve Gradient by Echo of
0 mm Hg and Progression Rate of AS of 5 mm Hg/Yr
Immediate 1 yr 5 yrs 10 yrs 15 yrs
ABG (%)
Event free 92.8 84.8 51.4 17.2 1.2
Successful reop AVR 0 4.0 19.8 31.6 29.3
Symptomatic AS 0 0.4 1.4 1.6 1.0
Morbid event 4.7 4.9 6.3 8.0 7.9
Death 2.5 5.9 21.1 41.6 60.6
ABG/AVR (%)
Event free 87.3 83.5 68.7 51.2 35.1
Morbid event 8.0 8.3 9.4 9.2 7.7
Death 4.7 7.5 22.0 39.7 57.1
bbreviations as in Tables 1 and 2.Cs in Figure 1.onths) for patients undergoing CABG alone. For young
atients with gradients above the threshold for performing
ABG/AVR, about 21 days are gained for every 5-mm Hg
ncrease in valve gradient. In older patients undergoing
ABG, about 10 days of life expectancy are gained for each
-mmHg decrease in valve gradient.
ffect of variation in the rate of AS progression. Figure 3
llustrates the effect of varying AS progression rate on the
ecision to undergo CABG surgery or CABG/AVR. At a
low progression of 3 mm Hg/year, nearly all patients with
symptomatic AS should undergo CABG alone. As the rate of
rogression increases to 11 mm Hg/year, virtually all patients
enefit from concomitant CABG/AVR.
ensitivity analysis of other variables. Treatment deci-
ions were not significantly affected by most other variables
ver clinical ranges (Table 1). Varying the rate of stroke or
leed from anticoagulation, probability of valve thrombosis,
ate of death with symptomatic AS, and changes in rates of
eath from operative morbidity had little impact on treat-
ent thresholds. Similarly, varying the quality-adjustment
atios for permanent morbidities made little difference in the
verall decision.
We also found that the model results changed little when
urgical morbidity and mortality rates were varied 20%
bove or below the STS national average. Finally, altering
he decision analysis model to allow for insertion of a
ioprosthesis in patients over age 70 years was superior, yet
ABG/AVR with bioprosthesis still impacts only a few
dditional patient scenarios.
In contrast, the value of one year of life on anticoagula-
ion therapy did affect the model’s conclusions. Specifically,
f patient displeasure from anticoagulation therapy reduces
he value of one year of life on warfarin by 10% or more,
hen essentially all patients with a baseline valve gradient
elow 50 mm Hg should receive CABG alone, on the basis
f the model data.
ISCUSSION
he clinical management of patients with mild or moderate
S at the time of coronary artery surgery remains a complex
roblem. This study is the first to incorporate a decision
nalysis approach as a means of simultaneously controlling
or many factors that can affect the ultimate decision
etween CABG and CABG/AVR strategies.
revious studies of AVR at the time of CABG. The
merican Heart Association/American College of Cardiol-
gy task force recommends valve replacement at the time of
oronary surgery if asymptomatic patients have severe AS,
ut the task force acknowledges limited data to support a
olicy of replacing a valve that exhibits only mild or
oderate AS (4). Small case series of CABG versus
ABG/AVR for mild to moderate AS patients exist and
ave had conflicting treatment recommendations. In one
eries, only 8 of 51 patients with mild AS (16%) who had
ABG alone required subsequent AVR at a mean of 71
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September 15, 2004:1241–7 AVR for Mild to Moderate AS at Time of CABGonths (27). Additionally, no differences in overall or
ardiac-related mortality were demonstrated among 476
atients with mild or moderate AS who underwent CABG/
VR (n  414) or CABG but not AVR (n  62), but the
stimated need for AVR (based on Kaplan-Meier event-free
urvival curves) at 72 months of follow-up was 24% in
atients who underwent CABG and only 3% in patients
ndergoing AVR (7). An analysis by Rahimtoola (28) used
urgical mortality and post-operative survival rates for
ABG or CABG/AVR from published reports to calculate
hat prophylactic AVR is contraindicated in most patients
ith mild or moderate AS. Unfortunately, this analysis used
ohorts of patients with coronary disease only as the basis
or the natural history after CABG surgery. Patients with
ny degree of AS are likely at higher risk, and comparing
heir outcomes with those of patients without AS biases this
rticle in favor of CABG surgery alone.
igure 3. As the rate of progression of aortic stenosis increases from 3 mm
g/year to 11 mm Hg/year, CABG alone (hatched areas) is favored in a
maller subset of patients. At a rate of 3 mm Hg/year, nearly all patients
ith mild AS should undergo CABG alone; at a rate of 11 mm Hg/year,
nly the elderly with very low gradients should be considered for CABG
Table 4. Absolute Differences in Quality-Adju
Valve Gradient (Rows) and Ages (Columns)
50 55
Peak aortic valve
gradient (mm Hg)
50 (3.15) (5.26) (5
45 (2.19) (4.15) (4
40 (1.21) (3.03) (3
35 (0.19) (1.88) (2
30 0.89 (0.69) (1
25 2.02 0.56 0
20 3.22 1.87 1
15 4.48 3.23 2
10 5.81 4.65 4
Bold values indicate survival advantage for CABG-alone st
CABG/AVR strategy.
Abbreviations as in Tables 1 and 2.oithout coincident AVR. Abbreviations as in Figure 1.nformation from the current study. The decision model
ermits tailoring of recommendations on the basis of patient
ge and valve gradient as shown in Figure 2. Assuming an
verage rate of progression of AS (5 mm Hg/year [1,9,29]),
atients under age 70 years with a valve gradient 30 mm
g benefit from CABG/AVR. For older patients, compet-
ng mortalities gradually increase the gradient threshold at
hich an AVR should be performed by roughly 1 to 2 mm
g/year. Although treatment decisions change, we should
ote that the absolute survival differences are generally small
xcept at the extremes of age and valve gradient.
A major finding from our sensitivity analysis was that
he rate of progression of AS greatly influences the
odel’s treatment recommendations. Thus, this study
mphasizes the need for tools to accurately assess AS
rogression for the individual patient. To date, case series
ave illustrated that the rate of progression may vary
arkedly among individuals (30 –33). If known (by serial
chocardiography), an individual’s rate of AS progression
hould replace our population averages (Fig. 3). In
ddition, this individual variability emphasizes the need
o determine reliable clinical predictors of AS progression
or those lacking serial echo measurements. Although
ge, valve calcification, progressive symptoms, and con-
omitant coronary disease (30 –33) have been cited as
redictors of AS progression, no uniform, consistent risk
actors for progression are currently in clinical use be-
ause of inconclusiveness of the above studies.
Roughly two-thirds of patients receive mechanical pros-
heses (34), but in patients over age 65 years a bioprosthesis
s usually recommended. Altering the current model to
eflect this practice had little effect because thromboembolic
nd anticoagulation-related complications were partially
ffset by the risk of valve failure. Although the favored valve
id shift with age, other variables were more critical in
etermining whether to replace the valve.
imitations of the current analysis. Our model had cer-
ain simplifying assumptions that should be noted. The risk
Survival (in Months) Across Peak Aortic
Ages (yrs)
65 70 75 80 85
(4.44) (3.85) (2.81) (1.14) (0.11)
(3.44) (2.95) (1.97) (0.45) 0.40
(2.45) (2.06) (1.15) 0.21 0.88
(1.45) (1.16) (0.34) 0.85 1.34
(0.43) (0.23) 0.48 1.49 .79
0.64 0.73 1.33 2.13 2.24
1.75 1.73 2.19 2.79 2.70
2.91 2.75 3.07 3.44 3.15
4.11 3.82 3.97 4.11 3.60
Parenthetical numbers indicate mean superior survival forsted
60
.62)
.47)
.33)
.19)
.02)
.20
.47
.79
.16
rategy.f prosthetic-valve endocarditis was not included because of
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AVR for Mild to Moderate AS at Time of CABG September 15, 2004:1241–7ery low rates (1% at year one) of prosthetic-valve endo-
arditis in recent series (35). Similarly, mechanical valve
ailure is uncommon in contemporary practice (36) and was
ot incorporated into the baseline model. Rates of mortality
or redo CABG or redo AVR for valve failure were not
onsidered because of the absence of reliable rates of these
vent occurrences, and because no reliable estimate of
ortality and morbidity rates during a redo-redo operation
xist. In addition, the possibility that a life-saving revascu-
arization procedure (redo CABG) may be performed at the
ime of an AVR for progressive AS or valve malfunction was
ot modeled. Rates of CABG mortality and morbidity are
rom the general STS database population and do not reflect
he fact that CABG patients with AS may actually have a
igher mortality rate at the time of the index operation (6).
ast, we chose to use valve gradient as our marker for
rogression and AS severity (rather than calculated valve
rea) because of the strong outcome data available regarding
he progression and prognosis of patients with AS of varying
egrees of severity (9), as well as the difficulties in calculat-
ng an accurate aortic valve area.
In addition, although patient age was an important factor
n the treatment decision, the valve replacement threshold
as directly dependent on life expectancy rather than age
er se. Comorbidities such as diabetes, lung disease, or
ermanent renal failure should be considered when deter-
ining appropriate treatment. In general, the trends illus-
rated in this manuscript (that younger patients with higher
aseline gradients or rapidly progressive AS should undergo
VR) and individual patient characteristics should have
ore bearing on the decision to replace a stenotic valve
ather than using an absolute valve gradient threshold for a
iven patient age.
linical recommendations. The current study provides
uidance to physicians and patients who are faced with a
ifficult clinical decision regarding replacement of a stenotic
ortic valve during coronary surgery. Three major factors
ffect the decision to perform CABG/AVR or CABG
lone: age (or life expectancy), baseline peak aortic valve
radient by echocardiography, and rate of AS progression.
ssuming an average rate of progression, CABG/AVR
hould be considered once the baseline gradient exceeds 30
m Hg. Individual patient characteristics, including co-
orbidities, local expertise in performing operations, and
atient preference are still important when making this
ifficult decision.
eprint requests and correspondence: Dr. Eric D. Peterson,
uke Clinical Research Institute, P.O. Box 17969, Durham,
orth Carolina 27715. E-mail: peter016@mc.duke.edu.
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